Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2020 Dec 14;17(12):e1003452. doi: 10.1371/journal.pmed.1003452

Genetic associations with temporal shifts in obesity and severe obesity during the obesity epidemic in Norway: A longitudinal population-based cohort (the HUNT Study)

Maria Brandkvist 1,2,3,*, Johan Håkon Bjørngaard 1,4, Rønnaug Astri Ødegård 2,3,5, Ben Brumpton 6,7,8, George Davey Smith 7,9, Bjørn Olav Åsvold 6,10,11, Erik R Sund 4,11,12, Kirsti Kvaløy 1,11,12, Cristen J Willer 13, Gunnhild Åberge Vie 1,3
Editor: Ronald C W Ma14
PMCID: PMC7735641  PMID: 33315864

Abstract

Background

Obesity has tripled worldwide since 1975 as environments are becoming more obesogenic. Our study investigates how changes in population weight and obesity over time are associated with genetic predisposition in the context of an obesogenic environment over 6 decades and examines the robustness of the findings using sibling design.

Methods and findings

A total of 67,110 individuals aged 13–80 years in the Nord-Trøndelag region of Norway participated with repeated standardized body mass index (BMI) measurements from 1966 to 2019 and were genotyped in a longitudinal population-based health study, the Trøndelag Health Study (the HUNT Study). Genotyping required survival to and participation in the HUNT Study in the 1990s or 2000s. Linear mixed models with observations nested within individuals were used to model the association between a genome-wide polygenic score (GPS) for BMI and BMI, while generalized estimating equations were used for obesity (BMI ≥ 30 kg/m2) and severe obesity (BMI ≥ 35 kg/m2).

The increase in the average BMI and prevalence of obesity was steeper among the genetically predisposed. Among 35-year-old men, the prevalence of obesity for the least predisposed tenth increased from 0.9% (95% confidence interval [CI] 0.6% to 1.2%) to 6.5% (95% CI 5.0% to 8.0%), while the most predisposed tenth increased from 14.2% (95% CI 12.6% to 15.7%) to 39.6% (95% CI 36.1% to 43.0%). Equivalently for women of the same age, the prevalence of obesity for the least predisposed tenth increased from 1.1% (95% CI 0.7% to1.5%) to 7.6% (95% CI 6.0% to 9.2%), while the most predisposed tenth increased from 15.4% (95% CI 13.7% to 17.2%) to 42.0% (95% CI 38.7% to 45.4%). Thus, for 35-year-old men and women, respectively, the absolute change in the prevalence of obesity from 1966 to 2019 was 19.8 percentage points (95% CI 16.2 to 23.5, p < 0.0001) and 20.0 percentage points (95% CI 16.4 to 23.7, p < 0.0001) greater for the most predisposed tenth compared with the least predisposed tenth, defined using the GPS for BMI. The corresponding absolute changes in the prevalence of severe obesity for men and women, respectively, were 8.5 percentage points (95% CI 6.3 to 10.7, p < 0.0001) and 12.6 percentage points (95% CI 9.6 to 15.6, p < 0.0001) greater for the most predisposed tenth. The greater increase in BMI in genetically predisposed individuals over time was apparent after adjustment for family-level confounding using a sibling design. Key limitations include a slightly lower survival to date of genetic testing for the older cohorts and that we apply a contemporary genetic score to past time periods. Future research should validate our findings using a polygenic risk score constructed from historical data.

Conclusions

In the context of increasingly obesogenic changes in our environment over 6 decades, our findings reveal a growing inequality in the risk for obesity and severe obesity across GPS tenths. Our results suggest that while obesity is a partially heritable trait, it is still modifiable by environmental factors. While it may be possible to identify those most susceptible to environmental change, who thus have the most to gain from preventive measures, efforts to reverse the obesogenic environment will benefit the whole population and help resolve the obesity epidemic.


In a longitudinal population-based cohort study in Norway, Maria Brandkvist and colleagues investigate how genetic predisposition relates to changes in BMI and obesity over the past six decades.

Author summary

Why was this study done?

  • Our genetic propensities for obesity may make it easier for some and more difficult for others to make healthy lifestyle choices, and for those with genetic predisposition to obesity, today’s environment may make these healthy lifestyle choices even more difficult.

  • Genetic predisposition can be measured with a new genetic tool encompassing over 2.1 million genetic variants associated with BMI.

  • How the effects of genetic predisposition to obesity differ as environments are becoming more obesogenic has not been quantified or validated using the genetic tool.

What did the researchers do and find?

  • We assessed the changes in the prevalence of obesity according to genetic predisposition over 6 decades in Norway, with increasing and stabilizing prevalence of obesity, using a genome-wide polygenic score (GPS) for BMI and validating by sibling design.

  • Using genetic data from 67,110 individuals aged 13–80 years with repeated height and weight measurements recorded between 1966 and 2019, we found that the prevalence of obesity differed between the participants with the highest and lowest genetic susceptibilities to obesity for all ages at each decade, and the difference increased gradually from the 1960s to the 2000s and then stabilized over the last decade.

  • For example, for 35-year-old men and women, the increase in the prevalence of obesity was 20 percentage points greater for the most genetically predisposed tenth compared with the least predisposed tenth.

What do these findings mean?

  • The results indicate that over the past 6 decades, the least genetically predisposed people seem relatively protected from obesity and almost completely protected from severe obesity, whereas the most predisposed people are at risk for both obesity and severe obesity, suggesting that an interplay between genes and an increasingly obesogenic environment could play a role in growing differences in obesity risk between individuals with varying genetic predisposition.

  • The findings from this study highlight the need to identify and to address the specific factors that led to the population-wide increase in obesity.

Introduction

Obesity is recognized as a disease associated with physical and psychiatric multimorbidities [1,2]. Approximately 60% to 80% of adults and 20% to 30% of children in the high-income countries are having overweight or obesity [3,4], while the prevalence in low- or middle-income countries is increasing substantially [5]. For a trait with 40% to 75% cross-sectional heritability [6,7], the body mass index (BMI) is still highly modifiable by the obesogenic environment [8,9]. Obesity can affect everyone regardless of genetic predisposition. However, across all age categories, not only are people with the genetic propensity for obesity at greater risk of excess weight, but also the impact of their genes is greater in the obesogenic environment of recent years [9].

Recently, a genome-wide polygenic score (GPS) was developed as a quantitative measure of inherited susceptibility for obesity [10]. Unlike the genetic risk score based on 97 genetic variants reaching genome-wide significance [11], the GPS encompasses over 2 million common genetic variants associated with BMI. Although not deterministic, this powerful polygenic tool explains 9% of variation for BMI suggesting a 13-kg weight gradient across polygenic score tenths among today’s middle-aged adults [10]. To put in context, the change in the mean BMI seen in many countries of the world between 1975 and 2014 is as large or larger than the difference in the BMI from the top to bottom decile of the GPS [12].

Our previous longitudinal analysis of the Trøndelag Health Study (the HUNT Study) [9] provides convincing evidence of the interplay between genes and the environment. This study focused on population BMI and applied a genetic risk score for BMI with 97 gene variants [11] over 5 decades. Utilizing the dramatic changes in our environment from 1966 to 2019, we now apply the more powerful GPS to show that the same trends exist with the prevalence of obesity.

Arguably, the increased disparity in weight between the genetically predisposed and non-predisposed in recent years could be attributed to assortative mating rather than a function of the obesogenic environment [13]. It is logical to assume that children of couples with obesity are likely to inherit a higher genetic risk for obesity and that genetic variance would amplify for each generation, in turn contributing to increasing obesity prevalence [13]. Confounding could also arise from population stratification, when allele frequencies differ between subpopulations, or from dynastic effects, when parental genes influence offspring outcome through other pathways than shared genes [1416]. As the GPS distribution between siblings sharing a mother and father is random, we use sibling design to compare BMI within families. This is important as it mitigates bias from assortative mating, population stratification, and dynastic effects [14]. Hence, the goal of this study is to quantify and validate the interplay between our genes and the environment.

Methods

Our study includes 67,110 individuals of European descent aged 13 to 80 years. The study population consists of participants from the HUNT Study (1984 to 2019) linked to previous height and weight measurements in the tuberculosis screening program (1966 to 1969). The entire adult population in the Nord-Trøndelag region was invited to participate in the HUNT Study conducted in 4 waves: HUNT1 (1984 to 1986), HUNT2 (1995 to 1997), HUNT3 (2006 to 2008), and HUNT4 (2017 to 2019). The Young-HUNT Study, recruiting all teenagers aged 13 to 19 years in the Nord-Trøndelag region, was conducted in 1995 to 1997, 2000 to 2001, 2006 to 2008, and 2017 to 2019. Despite participation decline from 88% in HUNT1 to 70% in HUNT2 and subsequently 54% in HUNT3 and HUNT4, the HUNT Study is considered as the representative of the Norwegian population [17]. The tuberculosis screening program was established in 1943 and contributed to the surveillance of tuberculosis in the general Norwegian population [18]. From the tuberculosis screening data, we limited height and weight data to the time interval with most observations from 1966 to 1969 and excluded participants younger than 14 years as they were not targets for total population surveillance.

BMI assessment

Measurements were standardized with weight measured to the nearest half kilogram with the participants wearing light clothes and no shoes, and height was measured to the nearest centimeter [19]. BMI was calculated using the formula weight in kilograms per meter squared. As defined by the World Health Organization, we refer to overweight as having BMI greater than or equal to 25 and to obesity as having BMI greater than or equal to 30 [20]. We chose to refer to severe obesity as having BMI greater than or equal to 35. As previously described, we calculated BMI z-scores for participants younger than 18 years [9]. By definition, BMI encompasses adjustments for height. However, a BMI of 30 does not necessarily have the same significance for a tall person as for a short person [21]. In the statistical analyses, we adjusted BMI for height to account for any effect of the 6-cm height increase in the population since the 1960s [22]. As suggested by the reviewers, we repeated the analyses using BMI without adjustment for height and compared the results.

Genotyping and computation of genome-wide polygenic score (GPS)

Genetic analyses were performed on blood samples collected from adults participating in HUNT2 and HUNT3 [23]. Genotyping was carried out with 1 of 3 different Illumina HumanCoreExome arrays (HumanCoreExome12 v1.0, HumanCoreExome12 v1.1, and UM HUNT Biobank v1.0, Illumina, California, United States of America), as described previously [9,24]. Imputation was performed using minimac3 (https://imputationserver.sph.umich.edu/) from a panel combined from the Haplotype Reference Consortium and 2,202 HUNT low-pass sequenced individuals with indel calling. We constructed a GPS using weights from the polygenic score for BMI derived and validated by Khera and colleagues. Detailed information on the polygenic score derivation and validation is described previously [10]. The GPS of Khera and colleagues includes 2.1 million common variants previously identified to be associated with BMI [11,25]. Palindromic polymorphisms were excluded; however, all available variants of sufficient quality were included regardless of the p-value of their association with BMI. Using a Bayesian approach, a posterior mean effect size was calculated for each variant encompassing the extent at which similarly associated variants correlated with each other in a reference population [10]. We included 2.07 million of the 2.1 million common variants, excluding those with insufficient quality of genotyping or imputation in HUNT (r2 < 0.8).

Statistical analysis

Prior to commencing the analyses, we modified the prospective analysis plan slightly in agreement with all coauthors. The prospective protocol and reasoning for modifications are included in the supplementary files (S1 Protocol, S1 Text). BMI was originally planned as a secondary outcome, and severe obesity was added as an outcome. As suggested by the editor, we present the distribution of participants according to both the GPS and the previously used GRS (Table A in S2 Text). We also show the mean BMI in the bottom and top tenths of genetic predisposition according to each score (Table B in S2 Text). These tables highlight the differences between the 2 genetic scores.

We assessed the association between GPS and BMI using linear multilevel models with observations nested within individuals. To assess linearity, we modeled the association between the GPS and BMI using linear splines with 9 knots according to percentiles of the distribution. We adjusted for sex and time of measurement as categorical variables and used linear splines with knots at every 20 years to adjust for age. We also adjusted for 20 principal components and genotyping batch. Further, we allowed the effect of the GPS to differ according to time of measurement, sex, and age using interaction terms for each. Although we adjusted for age using splines, we used 20-year age categories for the interaction terms. The association between the GPS and BMI was fairly linear justifying a linearity assumption for GPS (Fig A in S2 Text). Hence, for the main analyses, we divided the study population into 10 equally sized groups, the top tenth being the most genetically susceptible to higher BMI and the bottom tenth being the least genetically susceptible. We then estimated the effect of genetic risk of obesity on height-adjusted BMI according to time of measurement, age, and sex. In addition to the previously described interaction terms, we included an interaction term between age and time of measurement.

We modeled the association of GPS with obesity and severe obesity using generalized estimating equations. We included the same covariates as in the models assessing height-adjusted BMI. In the main text, we present results for adults aged 25 to 55 years, as this age band shows a relevant age span and was most complete in our dataset. Based on these models, we plotted the estimated height-adjusted BMI and the prevalence of obesity and severe obesity for the highest compared with the lowest tenth of genetic susceptibility to BMI for chosen ages at each decade for men and women. We report p-values from regression models based on Wald tests and marginal differences based on the delta method, both 2-sided and with significance level at 0.05.

Since the transmission of alleles from parent to offspring is random, the siblings have equal likelihood of inheriting any given genetic variant. To assess whether assortative mating, dynastic effects, or population stratification influenced the results, we analyzed the association of the GPS with height-adjusted BMI as well as with the prevalence of obesity within and between siblings. The sibships’ GPS average and each sibling’s deviation from the group GPS average were calculated and included as independent variables in the regression models with individuals clustered in sibships. We used maximum likelihood random-effects regression models for height-adjusted BMI and generalized estimated equation models for obesity and severe obesity. We adjusted for age with splines as previously described and included interaction terms between sex and each of the aforementioned measures of genetic predisposition. The within-sibship coefficient is an estimate for differentially genetically exposed siblings. Between-sibship coefficients exceeding the within-sibship coefficients would indicate confounding at the sibship level. Unlike the main analyses, we performed these models separately by time point with 1 observation per individual, assuming the association of GPS with BMI and with obesity to be linear and constant over different ages.

To assess the possibility of selection bias, we estimated the association between obesity status in the 1960s and availability of genetic data. We compared the estimated BMI and the prevalence of obesity among 38,378 individuals excluded due to the lack of genetic data to the estimated BMI and the prevalence of obesity for individuals in our study sample. We used genetic data from first-degree relatives to evaluate if exclusions due to missing genetic data biased the results. To approximate the relative rather than the absolute difference in BMI, we assessed the association between the GPS and the natural logarithm of BMI. Analyses were performed with StataMP 15 (Stata), StataMP 16 (Stata), and Plink 2.0 (cog-genomics.org). This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).

Ethics statement

The study obtained ethics approval from the Regional Committees for Medical and Health Research Ethics with ID 2016/537. All adult participants gave written informed consent before taking part in the HUNT Study. This consent included linkage to other registries. Parents gave written informed consent for adolescents taking part in the Young-HUNT Study.

Patient and public involvement

There was no patient and public involvement in planning the research question, the outcome measures, the design, or the implementation of the study. Neither were the patients and public asked to assess the burden of participation as only previously collected data were used. Involvement of the Norwegian organization Landsforening for Overvektige will be sought in setting an appropriate method of dissemination.

Results

The study sample consists of 67,110 participants aged 13 to 80 years with a total of 202,030 BMI measurements, with an average of 3 measurements per person (Fig 1). Although all ages were included in the analyses, we present age specific results for ages 25 to 55 years in the main results. The wider age range is presented in the Supporting information (Figs B and C in S2 Text). In the results, however, we chose to focus on BMI measurements from adult participants, as observations in the adolescent age range were limited (Table 1). The average age of participants increased gradually from 30 years in the 1960s to 60 years in 2017 to 2019, except for 2000 to 2001 when only adolescents participated. We found an increasing BMI variance and a shift toward a higher prevalence of obesity over time (Table 1, Figs D–F in S2 Text). In the contemporary HUNT population, the GPS explained 8.26% of variance in BMI.

Fig 1. Flowchart of study participants and criteria for inclusion in study sample.

Fig 1

*Linkage to data from tuberculosis screening program (1963–1975) required participation in HUNT2 (1995–1997) or HUNT3 (2006–2008). Participants could contribute with more than 1 observation in 1966–1969 or in rare cases in 1995–1997 or 2006–2008 by participating in both HUNT and YH. BMI, body mass index; HUNT, Trøndelag Health Study; YH, Young-HUNT.

Table 1. Descriptive statistics of male and female participants at each time point (SD and BMI).

Year TBC (1966–1969) HUNT1 (1984–1986) HUNT2 (1995–1996) YH2 (2000–2001) HUNT3 (2006–2008) HUNT4 (2017–2019) Total
Men
No. of participants 12,046 19,588 26,323 155 21,187 14,487 31,717
No. of observations 12,149 19,588 26,336 155 21,192 14,487 93,907
Mean age (SD) 30.4 (11.1) 42.4 (12.6) 47.6 (16.1) 18.1 (0.6) 52.3 (14.5) 60.2 (11.5) 47.2 (16.3)
Mean BMI (SD) 23.8 (2.8) 25.1 (3.0) 26.3 (3.5) 22.7 (3.3) 27.5 (3.8) 27.9 (4.0) 26.3 (3.7)
Smoking (%)
Never smokers 37.4 52.3 40.2
Former smokers 31.6 2.6 34.4
Current smokers 28.2 9.0 14.9
Missing 2.9 36.1 8.1
Education (%)
Primary 43.2 33.7 28.1 19.5 13.2
Secondary 50.3 53.9 54.6 58.2 60.7
Tertiary 5.5 12.1 15.2 22.0 26.0
Missing 1.0 0.3 2.1 0.2 0.1
Chronic disease (%) 31.3 19.3
Missing 5.6 29.9
Women
No. of participants 13,843 21,499 29,527 256 25,096 17,740 35,393
No. of observations 13,975 21,499 29,545 256 25,108 17,740 108,123
Mean age (SD) 31.0 (11.1) 42.6 (12.8) 47.1 (16.5) 18.2 (0.7) 51.2 (15.0) 58.9 (11.9) 47.0 (16.3)
Mean BMI (SD) 24.1 (3.8) 24.5 (4.1) 26.1 (4.6) 22.8 (3.3) 26.9 (4.9) 27.2 (4.9) 25.9 (4.7)
Smoking (%)
Never smokers 45.4 46.9 42.0
Former smokers 21.6 2.7 29.3
Current smokers 29.4 17.2 19.6
Missing 3.6 33.2 6.5
Education (%)
Primary 50.8 41.5 33.8 22.2 14.6
Secondary 43.5 47.1 46.9 48.7 48.1
Tertiary 5.0 11.1 16.8 28.8 37.1
Missing 0.8 0.3 2.4 0.3 0.1
Chronic disease (%) 30.1 18.9
Missing 7.7 28.9

Data on smoking and chronic diseases were not available in TBC, HUNT1, and HUNT4 for this project. Data on education were collected from Statistics Norway.

BMI, body mass index; HUNT, Trøndelag Health Study; SD, standard deviation; TBC, Tuberculosis Screening Program; YH, Young-HUNT.

From relative stability in the 1960s to 1980s, the BMI for both the genetically predisposed and non-predisposed increased dramatically from the mid-1980s to the 2000s and then stabilized to a higher level over the past decade. At different ages and decades, estimated height-adjusted BMI differed by 2.5 to 5 BMI units from top to bottom polygenic score tenths (Table 2). While the population BMI increased for both genetically predisposed and lesser predisposed people over time (Table D in S2 Text), the BMI increased more for the genetically predisposed (Table 3, Fig G in S2 Text). For instance, the difference in mean height-adjusted BMI between the most and least genetically predisposed tenths was 1.45 kg/m2 (1.09 to 1.81 kg/m2, p < 0.0001) greater in recent years compared with the 1960s. Additional analyses with BMI in models not adjusted for height asserted similar results (Fig H in S2 Text, Tables C, E, and F in S2 Text). We found comparable associations between polygenic risk score and BMI as well as obesity within and between sibling groups with little evidence of bias from assortative mating, population stratification, or dynastic effects (Fig 2, Fig I in S2 Text, Tables G and H in S2 Text). HUNT participants excluded due to missing genetic data had only a slightly higher BMI compared to participants with genetic data [9]. Using genetic data from first-degree relatives, we found no evidence that exclusion due to missing genetic data biased results (Figs J–L in S2 Text). Using the natural logarithm of BMI as the outcome, we found the expected larger effect sizes in more recent years (Table I in S2 Text).

Table 2. Estimated difference in height-adjusted BMI between the tenths with highest and lowest genetic susceptibilities at various time points.

Men Women
Time range Age Difference in BMI 95% CI p-value Difference in BMI 95% CI p-value
1966–1969 25 2.66 2.45 to 2.86 <0.001 3.53 3.33 to 3.73 <0.001
35 2.96 2.74 to 3.18 <0.001 3.83 3.62 to 4.05 <0.001
45 3.04 2.78 to 3.30 <0.001 3.91 3.65 to 4.18 <0.001
1984–1986 25 2.91 2.71 to 3.10 <0.001 3.78 3.59 to 3.97 <0.001
35 3.21 3.03 to 3.39 <0.001 4.08 3.91 to 4.25 <0.001
45 3.29 3.09 to 3.49 <0.001 4.16 3.97 to 4.36 <0.001
55 3.15 2.90 to 3.40 <0.001 4.02 3.78 to 4.27 <0.001
65 2.94 2.62 to 3.25 <0.001 3.81 3.49 to 4.13 <0.001
1995–1997 25 3.48 3.26 to 3.70 <0.001 4.35 4.14 to 4.56 <0.001
35 3.78 3.60 to 3.96 <0.001 4.65 4.48 to 4.83 <0.001
45 3.86 3.68 to 4.04 <0.001 4.74 4.56 to 4.91 <0.001
55 3.72 3.51 to 3.93 <0.001 4.60 4.39 to 4.80 <0.001
65 3.51 3.24 to 3.77 <0.001 4.38 4.12 to 4.65 <0.001
2006–2008 25 3.98 3.71 to 4.24 <0.001 4.85 4.59 to 5.11 <0.001
35 4.28 4.05 to 4.50 <0.001 5.15 4.94 to 5.37 <0.001
45 4.36 4.16 to 4.56 <0.001 5.23 5.04 to 5.42 <0.001
55 4.22 4.02 to 4.42 <0.001 5.09 4.90 to 5.28 <0.001
65 4.01 3.78 to 4.23 <0.001 4.88 4.66 to 5.10 <0.001
2017–2019 25 4.11 3.76 to 4.45 <0.001 4.98 4.65 to 5.31 <0.001
35 4.41 4.11 to 4.70 <0.001 5.28 4.99 to 5.57 <0.001
45 4.49 4.23 to 4.75 <0.001 5.36 5.11 to 5.61 <0.001
55 4.35 4.12 to 4.58 <0.001 5.22 5.00 to 5.44 <0.001
65 4.14 3.92 to 4.35 <0.001 5.01 4.80 to 5.22 <0.001

BMI, body mass index; CI, confidence interval.

Table 3. Estimated difference in height-adjusted BMI between the tenths with the highest and lowest genetic susceptibilities over time for all ages for men and women combined.

Time range BMI difference 95% CI p-value
1966–1986 0.25 0.09 to 0.41 0.002
1966–1997 0.82 0.61 to 1.03 <0.001
1966–2008 1.32 1.04 to 1.59 <0.001
1966–2019 1.45 1.09 to 1.81 <0.001

BMI, body mass index; CI, confidence interval.

Fig 2. Estimated OR (with 95% CI) for obesity per SD higher GPS for BMI within and between siblings by year.

Fig 2

Based on 29,585 individuals comprising 11,857 sibling groups within participants in the HUNT Study. BMI, body mass index; CI, confidence interval; GPS, genome-wide polygenic score; HUNT, Trøndelag Health Study; OR, odds ratio; SD, standard deviation.

The increase in the prevalence of obesity and severe obesity was observed to be steeper among the genetically predisposed over the time period (Figs 3 and 4). Among 35-year-old men, the prevalence of obesity for the least predisposed tenth increased from 0.9% (95% confidence interval [CI] 0.6% to 1.2%) to 6.5% (95% CI 5.0% to 8.0%, p for difference < 0.001), while the most predisposed tenth increased from 14.2% (95% CI 12.6% to 15.7%) to 39.6% (95% CI 36.1% to 43.0%, p for difference < 0.001). The absolute change in the prevalence of obesity was 19.8 percentage points (95% CI 16.2 to 23.5 percentage points, p < 0.0001) greater for the highly predisposed. Equivalently for women of the same age, the prevalence of obesity for the least predisposed tenth increased from 1.1% (95% CI 0.7% to 1.5%) to 7.6% (95% CI 6.0% to 9.2%, p for difference < 0.001), while the most predisposed tenth increased from 15.4% (95% CI 13.7% to 17.2%) to 42.0% (95% CI 38.7% to 45.4%, p for difference < 0.001). The absolute change in the prevalence of obesity among women was 20.0 percentage points (95% CI 16.4 to 23.7 percentage points, p < 0.0001) greater for the highly predisposed (Fig 3, Tables 4 and 5). A similar trend is evident for severe obesity (Fig 4, Tables 4 and 5); the corresponding absolute changes in the prevalence of severe obesity for men and women, respectively, were 8.5 percentage points (95% CI 6.3 to 10.7 percentage points, p < 0.0001) and 12.6 percentage points (95% CI 9.6 to 15.6 percentage points, p < 0.0001) greater for the highly predisposed. Similar yet slightly smaller changes were found among other ages. (Figs 3 and 4, Tables 4 and 5). With a contemporary prevalence of severe obesity below 2% for most age groups, the least genetically predisposed people seem relatively protected against severe obesity.

Fig 3. Estimated prevalence of obesity by top and bottom tenths of GPS.

Fig 3

Estimated prevalence (%, with 95% CI) of obesity (BMI ≥ 30 kg/m2) by top (most susceptible, circle) and bottom tenths (least susceptible, x) of GPS by age and time point for 31,717 men and 35,393 women who participated in the HUNT Study, Norway. *Youngest observed age in 2017–2019 was 28.6 years. BMI, body mass index; CI, confidence interval; GPS, genome-wide polygenic score; HUNT, Trøndelag Health Study.

Fig 4. Estimated prevalence of severe obesity by top and bottom tenths of GPS.

Fig 4

Estimated prevalence (%, with 95% CI) of severe obesity (BMI ≥ 35 kg/m2) by top (most susceptible, circle) and bottom tenths (least susceptible, x) of GPS by age and time point for 31,717 men and 35,393 women who participated in the HUNT Study, Norway *Youngest observed age in 2017–2019 was 28.6 years. BMI, body mass index; CI, confidence interval; GPS, genome-wide polygenic score; HUNT, Trøndelag Health Study.

Table 4. Percentage point increase in the prevalence of obesity and severe obesity over time for the tenths with the highest and lowest genetic susceptibilities.

Obesity Men Women
Time range Age GPS decile Increase in prevalence 95% CI p-value Increase in prevalence 95% CI p-value
1966–2019 25 0 3.04 1.57 to 4.51 <0.001 3.58 1.90 to 5.27 <0.001
9 21.21 14.64 to 27.78 <0.001 22.62 15.81 to 29.42 <0.001
35 0 5.55 4.06 to 7.03 <0.001 6.49 4.88 to 8.10 <0.001
9 25.29 21.61 to 28.97 <0.001 26.43 22.73 to 30.14 <0.001
45 0 7.52 5.69 to 9.35 <0.001 8.73 6.79 to 10.66 <0.001
9 20.81 17.23 to 24.38 <0.001 21.36 17.74 to 24.99 <0.001
1984–2019 55 0 8.65 7.09 to 10.22 <0.001 9.99 8.37 to 11.61 <0.001
9 21.39 18.81 to 23.97 <0.001 21.97 19.36 to 24.58 <0.001
65 0 7.52 5.92 to 9.13 <0.001 8.65 6.96 to 10.35 <0.001
9 12.72 9.71 to 15.73 <0.001 12.99 9.91 to 16.07 <0.001
Severe obesity Men Women
Time range Age GPS decile Increase in prevalence 95% CI p-value Increase in prevalence 95% CI p-value
1966–2019 25 0 0.54 0.01 to 1.07 0.044 1.39 0.15 to 2.63 0.028
9 7.12 3.18 to 11.06 <0.001 11.44 5.52 to 17.37 <0.001
35 0 0.73 0.29 to 1.17 0.001 1.87 1.00 to 2.74 <0.001
9 9.18 6.94 to 11.42 <0.001 14.38 11.32 to 17.43 <0.001
45 0 0.93 0.41 to 1.44 <0.001 2.35 1.38 to 3.33 <0.001
9 8.52 6.49 to 10.56 <0.001 13.03 10.26 to 15.80 <0.001
1984–2019 55 0 1.02 0.47 to 1.56 <0.001 2.57 1.69 to 3.45 <0.001
9 6.85 5.32 to 8.37 <0.001 10.42 8.37 to 12.48 <0.001
65 0 0.89 0.40 to 1.38 <0.001 2.24 1.32 to 3.16 <0.001
9 3.48 1.78 to 5.18 <0.001 5.25 2.75 to 7.74 <0.001

The percentage point increase is the difference between the estimated prevalence at the earliest time point subtracted from the estimated prevalence at the most recent time point.

CI, confidence interval; GPS, genome-wide polygenic score.

Table 5. Difference in percentage point increase of prevalence in obesity and severe obesity between the tenths with the highest and lowest genetic susceptibilities over time.

Obesity Men Women
Time range Age Difference in increase 95% CI p-value Difference in increase 95% CI p-value
1966–2019 25 18.24 12.43 to 24.05 <0.0001 19.11 13.19 to 25.03 <0.0001
35 19.84 16.19 to 23.49 <0.0001 20.04 16.37 to 23.70 <0.0001
45 13.40 9.47 to 17.33 <0.0001 12.74 8.73 to 16.76 <0.0001
1984–2019 55 8.96 5.90 to 12.02 <0.0001 8.19 5.06 to 11.32 <0.0001
65 5.34 2.11 to 8.58 0.0012 4.48 1.16 to 7.79 0.0081
Severe obesity Men Women
Time range Age Difference in increase 95% CI p-value Difference in increase 95% CI p-value
1966–2019 25 6.60 2.85 to 10.36 0.0006 10.10 4.62 to 15.57 0.0003
35 8.49 6.27 to 10.71 <0.0001 12.57 9.57 to 15.58 <0.0001
45 7.66 5.58 to 9.74 <0.0001 10.76 7.88 to 13.63 <0.0001
1984–2019 55 4.00 2.40 to 5.59 <0.0001 5.18 2.90 to 7.48 <0.0001
65 2.67 0.94 to 4.39 0.0024 3.11 0.57 to 5.65 0.0163

For each age category and each sex, the estimated difference in percentage point increase equals the difference between percentage points increase in prevalence over time for the highest compared to the lowest genetically predisposed tenth presented in Table 4.

CI, confidence interval.

Discussion

In this study, we observed that from the 1960s to the late 2010s, the prevalence of obesity and severe obesity increased dramatically for the genetically predisposed yet remained relatively unchanged for the least genetically predisposed. For 35-year-old men and women, the absolute increase in prevalence of obesity using the GPS was 20 percentage points greater for the most genetically predisposed tenth compared with the least predisposed tenth. This suggests an increasing genetic inequality in obesity and severe obesity over time, consistent with the increasingly obesogenic environment [5] and the increasing variance in BMI seen over time in many countries [26]. Interestingly, the increase in severe obesity across GPS tenths was strongest among women. Conceptualizing the year of assessment as a broad indicator of the obesogenic environment, our study illustrates that despite being a very heritable trait, body weight seems modifiable by obesogenic exposure. Further, our findings demonstrate an interplay between genes and the environment that is robust to family-level confounding using sibling design.

Comparison with other studies

In the Norwegian population of today, we found similarly explained variance for BMI and weight gradients across polygenic score tenths as previously described in contemporary British populations [10]. Although we acknowledge that both populations are of European decent, this affirms the GPS in a different cultural–geographic region. It is however notable that participation in the UK Biobank study is comparatively low (5%) and may be subject to participation bias where higher levels of adiposity reduced participation [27]. Compared to the British study, our study lacks statistical power in the younger age groups and could not replicate findings of an increasing weight gradient across polygenic score tenths from childhood to early adulthood [10]. Our dataset is however robust from age 25 to 75 years and does not affirm any clear age trends.

Combining the GPS with the dimension of time, our study suggests greater amplification of the effect of genetic predisposition on BMI during the obesity epidemic than previously shown [8,9]. Today’s prevalence of obesity is a net result of the effects of the obesogenic environment added to genetic differences plus the interplay between genes and the environment. The relatively stable prevalence of obesity from the 1960s to the 1980s in our study could reflect a relatively stable environment with a constant genetic contribution to BMI in the population. From the mid-1980s, Norway experienced increased prosperity resulting in new working cultures, increased market consumption and automobile transport, as well as an unfavorable change in dietary patterns [28,29]. With the introduction of an obesogenic environment, the prevalence of obesity increased but so did the discrepancy in obesity status between the genetically predisposed and non-predisposed. These trends then level off as the prevalence of obesity stabilized over the last decade. In line with previous studies, we find a change in the distribution of BMI with an increasingly positive skew [26,30]. Our findings comply with a recent twin study collaboration suggesting unchanged heritability estimates for BMI over time and geography as a result of both increasing average BMI and an increasing impact of the environment on the effects of genetic variation [31,32]. A possible explanation comes from another study suggesting that the effect of certain genetic variants associated with obesity increase in people with higher BMI, and the enhanced genetic effects stem predominantly from gene by environment interactions [33].

Strengths and limitations of this study

Our study provides statistical evidence for the changing effect of genetics on obesity over time. Although previous studies indicated that genetic variants known to predict BMI had larger effects after the onset of the obesity epidemic than before [8,9], to the best of our knowledge, this study includes the largest sample size and range of years of assessments and ages to date. Compared with our previous analysis of the HUNT Study population [9], BMI measurements as late as 2019 illustrate how genetic inequality in BMI stabilizes as the population weight levels off. Our study sample is considered unselected and is little affected by nonparticipation bias or bias from selective survival to date of genetic testing, as previously described [9]. For the eldest cohorts, we acknowledge a weak association between BMI measured in the 1960s and survival to and participation in genetic analyses in the 1990s. Still, we found little evidence of selection bias in analyses using genetic data from first-degree relatives as a proxy for those who did not participate in genetic testing. Also, results for 25-year-old men and women in 2017 to 2019 are extrapolated from a broader age range.

Combining this unique dataset with such a powerful polygenic predictor is the principal strength of our study. Although the GPS does not account for the effect of rare gene variants recently recovered by whole-genome sequencing [6], it is the first genetic instrument to provide meaningful predictive power by encompassing over 2 million common gene variants associated with obesity. Compared with the previous score [9], the increase in explained variance from 3% to 9% may appear small. However, this reflects a substantially greater difference in BMI between the genetically predisposed and lesser predisposed and improves the classification of genetic risk considerably (Tables E and F in S2 Text). Among today’s middle-aged adults, this difference amounts to a 13-kg weight gradient across polygenic score tenths [10]. We applied the contemporary GPS to past time periods in the absence of historical data from a separate population. Ideally, with access to a GPS from the past, we could examine if the increased effect of genetic risk on BMI still occurs. Future research should focus on constructing a polygenic risk score from historical data.

In this study, we validate our findings in within-sibship analyses, which suggest that neither assortative mating, dynastic effects, nor fine-scale population stratification issues generate the results we see [14,15,34]. However, we recognize that parents of participants in our cohort met before the start of the obesity epidemic in the mid-1980s, and genotypic assortment for BMI might be a greater issue in the future.

Generalizability of the findings

The effect of the obesogenic environment on population weight acts partly through enhancing the effect of our genes [9]. The magnitude seems to relate to the obesogenic exposure in the macroenvironment, conceptualized as year of assessment in this study. In contrast to most countries [5,35], the prevalence of obesity in Norway stabilized over the last decade. As a result, we observe a stabilizing gradient in weight and only a slight increased risk of obesity across polygenic score tenths. Although difficult to measure, this finding could indicate a consistent obesogenic exposure in the macroenvironment in recent years. However, in countries where obesity prevalence is still increasing, these weight gradient trends across genetic susceptibility would likely be different.

Implications and future research, clinical practice, and public policy

Our findings suggest a genetic inequality in obesity during the obesity epidemic in Norway. This novel insight may help identify those susceptible to environmental change as a preventative measure.

Future research should focus on specific gene environment interactions that could help determine which preventative efforts are most effective. Regardless, secular trends have increased body weight for both genetically predisposed and genetically non-predisposed people. It is time for the global community to recognize and to address the determinants of ill health that foster the unhealthy environment in which we live [5,36].

Conclusions

The prevalence of obesity increased substantially from the mid-1980s and has stabilized to a new level over the last decade in the Norwegian population. While obesity is a highly heritable trait [6], our study illustrates how it is still modifiable by the obesogenic exposure. Utilizing the substantial changes in our environment over time, we expose a growing inequality in risk for obesity and severe obesity between the genetically predisposed and lesser predisposed. The magnitude of our findings using the GPS is far greater than previously anticipated, holds true over time, and is robust to confounding.

Supporting information

S1 Protocol. Prospective protocol.

(DOCX)

S1 Text. Modifications to the prospective protocol with rationale.

(DOCX)

S2 Text. Supporting figures and tables.

(DOCX)

S1 Checklist. Strengthening the reporting of observational studies in epidemiology.

(DOC)

Acknowledgments

The Trøndelag Health Study (the HUNT Study) is a collaboration between HUNT Research Centre, (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), the Nord-Trøndelag County Council, the Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National Institutes of Health (NIH); University of Michigan; The Research Council of Norway; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olavs University Hospital and the Faculty of Medicine and Health Sciences, NTNU. The genotype quality control and imputation has been conducted by the K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU).

Abbreviations

BMI

body mass index

CI

confidence interval

GPS

genome-wide polygenic score

HUNT

Trøndelag Health Study

STROBE

Strengthening the Reporting of Observational Studies in Epidemiology

Data Availability

Data from the HUNT Study can be made available to qualified researchers upon request to the HUNT Data Access Committee (hunt@medisin.ntnu.no). The data availability policy for the HUNT study is available here: (http://www.ntnu.edu/hunt/data). Data are only available to research groups with a PI affiliated with a Norwegian research institute. The Norwegian Institute of Public Health will consider applications for data from the Tuberculosis screening program through www.helsedata.no. Linkages require ethical clearance by the Regional Ethical Committees, more information is available at https://rekportalen.no/.

Funding Statement

Funding: MB was funded by The Liaison Committee for Education, Research and Innovation in Central Norway (https://helse-midt.no/samarbeidsorganet) with project number 90057601 and GÅV was funded by the Norwegian Research Council (https://www.forskningsradet.no/en/) with grant number 250335. JHB was funded by the Norwegian Research Council with grant number 295989. BB and BOÅ work in a research unit funded by Stiftelsen Kristian Gerhard Jebsen (https://stiftkgj.no/what-we-do/k-g-jebsen-centres-of-medical-research/?lang=en); Faculty of Medicine and Health Sciences, NTNU; The Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU; and the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council and the University of Bristol. GDS works in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (http://www.bristol.ac.uk/integrative-epidemiology/) MC_UU_00011/1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.King DE, Xiang J, Pilkerton CS. Multimorbidity Trends in United States Adults, 1988–2014. J Am Board Fam Med. 2018;31(4):503–13. 10.3122/jabfm.2018.04.180008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Duncan AE, Ziobrowski HN, Nicol G. The Prevalence of Past 12-Month and Lifetime DSM-IV Eating Disorders by BMI Category in US Men and Women. Eur Eat Disord Rev. 2017;25(3):165–71. [DOI] [PubMed] [Google Scholar]
  • 3.Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–67. 10.1016/S0140-6736(10)62037-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of Obesity and Severe Obesity in US Children, 1999–2016. Pediatrics. 2018;141(3):e20173459 10.1542/peds.2017-3459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Miranda JJ, Barrientos-Gutiérrez T, Corvalan C, Hyder AA, Lazo-Porras M, Oni T, et al. Understanding the rise of cardiometabolic diseases in low- and middle-income countries. Nat Med. 2019;25(11):1667–79. 10.1038/s41591-019-0644-7 [DOI] [PubMed] [Google Scholar]
  • 6.Wainschtein P, Jain DP, Yengo L, Zheng Z, Cupples LA, Shadyab AH, et al. Recovery of trait heritability from whole genome sequence data. bioRxiv. 2019. [cited 2020 Oct 19]. https://www.biorxiv.org/content/biorxiv/early/2019/03/25/588020.full.pdf. [Google Scholar]
  • 7.Stryjecki C, Alyass A, Meyre D. Ethnic and population differences in the genetic predisposition to human obesity. Obes Rev. 2018;19(1):62–80. 10.1111/obr.12604 [DOI] [PubMed] [Google Scholar]
  • 8.Walter S, Mejia-Guevara I, Estrada K, Liu SY, Glymour MM. Association of a Genetic Risk Score With Body Mass Index Across Different Birth Cohorts. JAMA. 2016;316(1):63–9. 10.1001/jama.2016.8729 [DOI] [PubMed] [Google Scholar]
  • 9.Brandkvist M, Bjorngaard JH, Odegard RA, Asvold BO, Sund ER, Vie GA. Quantifying the impact of genes on body mass index during the obesity epidemic: longitudinal findings from the HUNT Study. BMJ. 2019;366:l4067 10.1136/bmj.l4067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Khera AV, Chaffin M, Wade KH, Zahid S, Brancale J, Xia R, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. Cell. 2019;177(3):587–96.e9. 10.1016/j.cell.2019.03.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206. 10.1038/nature14177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–96. 10.1016/S0140-6736(16)30054-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hebebrand J, Wulftange H, Goerg T, Ziegler A, Hinney A, Barth N, et al. Epidemic obesity: are genetic factors involved via increased rates of assortative mating? Int J Obes Relat Metab Disord. 2000;24(3):345–53. 10.1038/sj.ijo.0801135 [DOI] [PubMed] [Google Scholar]
  • 14.Brumpton B, Sanderson E, Heilbron K, Hartwig FP, Harrison S, Vie G, et al. Avoiding dynastic, assortative mating, and population stratification biases in Mendelian randomization through within-family analyses. Nature communications. 2020;11(1):3519 10.1038/s41467-020-17117-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kong A, Thorleifsson G, Frigge ML, Vilhjalmsson BJ, Young AI, Thorgeirsson TE, et al. The nature of nurture: Effects of parental genotypes. Science. 2018;359(6374):424 10.1126/science.aan6877 [DOI] [PubMed] [Google Scholar]
  • 16.Morris TT, Davies NM, Hemani G, Smith GD. Population phenomena inflate genetic associations of complex social traits. Sci Adv. 2020;6(16):eaay0328 10.1126/sciadv.aay0328 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol. 2012;12:143 10.1186/1471-2288-12-143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Bjorge T, Engeland A, Tverdal A, Smith GD. Body mass index in adolescence in relation to cause-specific mortality: a follow-up of 230,000 Norwegian adolescents. Am J Epidemiol. 2008;168(1):30–7. 10.1093/aje/kwn096 [DOI] [PubMed] [Google Scholar]
  • 19.Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol. 2013;42(4):968–77. 10.1093/ije/dys095 [DOI] [PubMed] [Google Scholar]
  • 20.World Health Organization. Obesity and overweight [Internet]. 2020. http://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight.
  • 21.Michels KB, Greenland S, Rosner BA. Does body mass index adequately capture the relation of body composition and body size to health outcomes? Am J Epidemiol. 1998;147(2):167–72. 10.1093/oxfordjournals.aje.a009430 [DOI] [PubMed] [Google Scholar]
  • 22.Roser M, Appel C, Ritchie H. Human Height. May 2019 [2019 Sep 3]. [Internet]. 2013. https://ourworldindata.org/human-height.
  • 23.Hunt Research Center. HUNT Databank [Internet]. 2020. https://hunt-db.medisin.ntnu.no/hunt-db/#/.
  • 24.Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018;50(9):1234–9. 10.1038/s41588-018-0171-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. 10.1038/nature15393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Smith GD. A fatter, healthier but more unequal world. Lancet. 2016;387(10026):1349–50. 10.1016/S0140-6736(16)00588-2 [DOI] [PubMed] [Google Scholar]
  • 27.Tyrrell J, Zheng J, Beaumont R, Hinton K, Richardson TG, Wood AR, et al. Genetic predictors of participation in optional components of UK Biobank. bioRxiv. 2020. [cited 2020 Oct 19]. https://www.biorxiv.org/content/biorxiv/early/2020/02/10/2020.02.10.941328.full.pdf. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Monsrud J. The car became ubiquited in 1960 [Internet]. 1999. https://www.ssb.no/transport-og-reiseliv/artikler-og-publikasjoner/bilen-ble-allemannseie-i-1960.
  • 29.Consumed amounts of food and beverages per person per year, by commodity group. 1958–1998 [Internet]. Statistics Norway. https://www.ssb.no/a/histstat/aarbok/ht-0502-222.html.
  • 30.Razak F, Subramanian SV, Sarma S, Kawachi I, Berkman L, Davey Smith G, et al. Association between population mean and distribution of deviance in demographic surveys from 65 countries: cross sectional study. BMJ. 2018;362:k3147 10.1136/bmj.k3147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Silventoinen K, Jelenkovic A, Yokoyama Y, Sund R, Sugawara M, Tanaka M, et al. The CODATwins Project: The Current Status and Recent Findings of COllaborative Project of Development of Anthropometrical Measures in Twins. Twin Res Human Genet. 2019:1–9. 10.1017/thg.2019.35 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Silventoinen K, Jelenkovic A, Sund R, Yokoyama Y, Hur YM, Cozen W, et al. Differences in genetic and environmental variation in adult BMI by sex, age, time period, and region: an individual-based pooled analysis of 40 twin cohorts. Am J Clin Nutr. 2017;106(2):457–66. 10.3945/ajcn.117.153643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Abadi A, Alyass A, Robiou du Pont S, Bolker B, Singh P, Mohan V, et al. Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. Am J Hum Genet. 2017;101(6):925–38. 10.1016/j.ajhg.2017.10.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Young AI, Benonisdottir S, Przeworski M, Kong A. Deconstructing the sources of genotype-phenotype associations in humans. Science. 2019;365(6460):1396–400. 10.1126/science.aax3710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Adult obesity facts [Internet]. 2018. https://www.cdc.gov/obesity/data/adult.html.
  • 36.Lustig RH. Processed food-an experiment that failed. JAMA Pediatr. 2017;171(3):212–4. 10.1001/jamapediatrics.2016.4136 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Caitlin Moyer

21 May 2020

Dear Dr Brandkvist,

Thank you for submitting your manuscript entitled "Genetic inequalities in obesity and severe obesity during the obesity epidemic: longitudinal findings from the HUNT Study verified by sibling design" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff, as well as by an academic editor with relevant expertise, and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by .

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosmedicine@plos.org, or 'reply all' to this message if you have any queries relating to your submission.

Kind regards,

Caitlin Moyer, Ph.D.,

Associate Editor

PLOS Medicine

Decision Letter 1

Emma Veitch

7 Jul 2020

Dear Dr. Brandkvist,

Thank you very much for submitting your manuscript "Genetic inequalities in obesity and severe obesity during the obesity epidemic: longitudinal findings from the HUNT Study verified by sibling design" (PMEDICINE-D-20-01911R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to three independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Jul 28 2020 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Emma Veitch, PhD

PLOS Medicine

On behalf of Clare Stone, PhD, Acting Chief Editor,

PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Requests from the editors:

*One reviewer comments on the overlap between the analyses in this paper and those in a recent BMJ article, focussing on the effect of a 97-variant genetic risk score and obesity risk. The editors felt that these concerns did not invalidate the paper from further consideration in PLOS Medicine but it would be good to try to be more clear in the paper what is the value and novel contribution of the present genome-wide score.

*Please include a brief note in the last sentence of the Abstract Methods and Findings section summarising any key limitation(s) of the study's methodology.

*At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

*Please clarify, ideally in the Methods section, if the analytical approach used in this paper corresponded to one laid out in a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c) In either case, changes in the analysis-- including those made in response to peer review comments-- should be identified as such in the Methods section of the paper, with rationale.

-----------------------------------------------------------

Comments from the reviewers:

Reviewer #1: Reviewer comments provided in an attached document.

-----------------------------------------------------------

Reviewer #2: Brandkvist et al. demonstrate an increase in effect of a genetic score for BMI over time. The study is well written and the methods appear adequate for the research question. I only have minor comments that I feel should be adressed before the manuscript is accepted for publication.

The main result, an increase in genetic effect over time, is interpreted as a consequence of an increasingly obesogenic environment. I agree that this is the likely causal factor. However the authors need to argue from reported environmental observations that are relevant for the cohort used in the study. I would appreciate references to reports that have measured changing habits in activity and food intake for Norwegians, preferably in the Nord-Trøndelag region or a comparable population such as other Scandinavians, for the time period in question.

In addition, the phrasing in the discussion: "Our findings show an interplay between genes and the environment [..]", should be modified since environmental factors were not included in statistical models. Rather, they were inferred by assumption of changes in environment over time with no reference to measured or reported data on environmental factors.

Figures 3 and 4 are missing legends.

-----------------------------------------------------------

Reviewer #3: Study by Brandkvist and colleagues:

1-The authors recently published a study investigating the same question with a 97 SNP-based polygenic score versus a genome-wide polygenic score here. As these scores respectively explain 2.7% and 9% of BMI variation in the population, we do not expect very different conclusions from the two studies. In that context, the results of the current study, while interesting, have a limited incremental value.

2-The authors concluded that the increase in the prevalence of obesity during the 60 years follow-up was steeper among the genetically predisposed (low genetic risk: 35 year-old men: from 1% to 7%, 35 year-old women: from 1% to 8%; high genetic risk: 35 year-old men: from 14% to 40%; 35 year-old women: from 15% to 42%). This statement is true if we consider absolute changes in the prevalence of obesity. However, another way to look at the data is to consider that the prevalence of obesity was multiplied by 7-8 fold in the low genetic risk group versus 2.8-2.85 fold in the high genetic risk group during the last decades. With these data in mind, it looks like the obesogenic environment had a more detrimental impact on the development of obesity in the low genetic risk than the high genetic risk group ('environmental' obesity). Interpreting the data while considering the relative versus absolute changes in the prevalence of obesity is probably worth it.

3-The authors focused on 35-year old populations as it maximizes the statistical power. It may be relevant to perform sensibility analyses to make sure that the results observed in this age group can be generalized to younger and older people in the HUNT study.

4-'adults…children…are overweight or obese'. Please use people first language (adults…children…are having overweight or obesity').

5-The authors mention a heritability estimate of 40% for BMI. Heritability can be measured using different designs (twins, families, general populations). Please mention a heritability range of 40-75% (see the recent meta-analysis of heritability studies by Strijecky et al. Obes Rev 2018).

6-'fat mass, as indicated by body mass index'. BMI is a poor surrogate of fat mass in non-obese populations. I suggest rephrasing the sentence. The authors can focus on BMI heritability estimates, or can cite heritability studies for fat mass.

7-As BMI equals weight divided by height square, it is questionable to adjust BMI for height in my opinion (lack of independence between the covariate and the outcome).

8-The authors did not mention any transformation for BMI (ex. logarithmic, ranked-based inverse normal transformation). These transformations are frequently used in literature to correct for the lack of normality of the BMI distribution.

9-The authors may describe in more detail what were the changes of weight / BMI across time both globally and in the genetic subgroups in the Results section.

10-In the discussion, the authors may cite and comment the paper by Abadi et al. Am J Hum Genet 2017. This study suggests the existence of 'snowball' obesity genes that may provide a nice mechanistic explanation for the results of the HUNT study.

-----------------------------------------------------------

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 2

Caitlin Moyer

14 Sep 2020

Dear Dr. Brandkvist,

Thank you very much for submitting your manuscript "Genetic inequalities in obesity and severe obesity during the obesity epidemic: longitudinal findings from the HUNT Study verified by sibling design" (PMEDICINE-D-20-01911R2) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to a statistical reviewer for re-review. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

Although we note that Reviewer 1 has no further concerns, a few remaining issues to address were noted by the Academic Editor and editorial team. I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that fully addresses the editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response.

In revising the manuscript for further consideration, your revisions should fully address the specific points made by the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Sep 28 2020 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Caitlin Moyer, PhD

Associate Editor

PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Requests from the editors:

1.Comments from the Academic Editor: Response to Reviewer 3: Please include tables 1 and 2 from your response to Reviewer 3’s comments in the text of the manuscript (comparing the performance of the earlier GRS versus the more recent polygenic risk score) as this is helpful to emphasizing the advance of this study compared to previous reports using genetic risk score.

2.Comments from the Academic Editor: Please make it clear in the text why a number of significantly younger individuals with lower BMI from YHUNT2 were included in a dataset of otherwise older individuals (see table S1 and S3).

3. Response to Reviewer 3: Please add the additional sensitivity analysis done with BMI not adjusted for height to the supporting information files and refer to these in the Methods and Results (in response to Reviewer 3 comment 7).

4. Competing Interests: Please add this statement to the manuscript's Competing Interests: "GDS is an Academic Editor on PLOS Medicine's editorial board.”

5. Abstract: Methods and Findings: In the first sentence, a comma is missing from “67 110 individuals” (The comma is similarly missing from this number in the Author Summary, Methods, and Results sections).

6. Abstract: Methods and Findings: Please revise this sentence, as your study did not formally test a gene x environment interaction. We suggest: “The greater increase in BMI in genetically predisposed individuals over time was apparent after adjustment for family-level confounding using a sibling design.” or similar.

7. Abstract: Methods and Findings: Please clarify what is meant by “slight differential survival to date of genetic testing” in the limitations statement.

8. Abstract: Methods and Findings: Please include both 95% CIs and p values for all results presented here.

9. Abstract: Conclusions: * Please address the study implications without overreaching what can be concluded from the data; For the Conclusions paragraph, we suggest the following revision; “In the context of increasingly obesogenic changes in our environment over six decades, our findings reveal a growing inequality in risk for obesity and severe obesity across genome-wide polygenic score tenths. Our results suggest that while obesity is a heritable trait at least in part, it is still modifiable by environmental factors. Whilst it may be possible to identify those most susceptible to environmental change, who thus have the most to gain from preventive measures, efforts to reverse the obesogenic environment will benefit the whole population and help resolve the obesity epidemic.”

10. Author Summary: Please structure the Author Summary using bullet points for each point, and restrict the number of points to 3 per section, and 1 sentence per bullet point, if possible. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

11. Author Summary: Why was this study done? In the 3rd point of this section, please remove the word "powerful" " In the 4th point of this section, please remove “vastly more powerful” as this is not informative.

12.Author Summary: What did the researchers do and find?: Please revise to (or similar):

--We assessed the relationship between an obesogenic environment and the prevalence of obesity according to genetic predisposition over six decades in Norway, with increasing and stabilizing prevalence of obesity, using a genome-wide polygenic score for BMI and validating by sibling design.

--Using genetic data from 67,110 individuals aged 13 to 80 years with repeated height and weight measurements recorded between 1966 and 2019, we found that the prevalence of obesity differed between the participants with the highest and lowest genetic susceptibility to obesity for all ages at each decade, and the difference increased gradually from the 1960s to the 2000s to then stabilize over the last decade

.

--For example, for 35 year old men and women, the increase in prevalence of obesity was 20 percentage points greater for the most genetically predisposed tenth compared with the least predisposed tenth.

13. Citations: For in-text citations, please use square brackets rather than parentheses and place citations before the punctuation, like this [1].

14. Introduction: First paragraph: Please replace the terms “developing” and “western world” by referring to high income countries rather than "developed" or "Western" countries, and to low or middle income countries rather than "developing countries"

15. Introduction: Last paragraph: Please revise to “This is important as it mitigates bias…”

16. Introduction: Please conclude the Introduction with a clear description of the study question or hypothesis. Final sentence: Please revise to remove “the most powerful” as this is hyperbole. We suggest: “Hence, the goal of this study is to quantify and validate the interplay between our genes and the environment.” or similar.

17.Methods: First paragraph: Please clarify the ages of the participants, as the first sentence states you included individuals aged 13 or older, and the last sentence indicates you did not include individuals aged younger than 14. (Please also be sure this is consistent throughout the manuscript)

18. Methods: Ethical approval: Please note the nature of informed consent (e.g. written informed consent).

19. Methods: Page 10: Please provide additional details on how the sibling analyses were done and how this strengthens the study.

20. Methods: Statistical analysis: Please specify the significance level used to determine whether there were differences in your results (eg, P<0.05, two-sided) as well as the statistical test used to derive a p value.

21. Results: Please present the findings quantified with 95% CIs and p values to reflect statistical differences of comparisons referred to in the text. Specifically, please provide quantitative results, 95% CIs and p values for the increase in BMI/prevalence of obesity over time overall and for genetically predisposed vs. not predisposed groups. Please provide both the height adjusted and unadjusted analyses.

22. Results: Please present the results of sibling analyses with 95%CIs and p values “We found comparable associations between polygenic risk score and BMI as well as obesity within and between sibling groups with little evidence of bias from assortative mating, population stratification or dynastic effects (Fig 2, S6 Fig)”

23. Results: Page 12: Please provide the statistical results to substantiate this sentence, or change this to “observed to be steeper” or “apparently steeper” to indicate that this was not statistically tested. “The increase in prevalence of obesity and severe obesity was steeper among the genetically predisposed over the time period (Fig 3, Fig 4).”

24. Results Page 12-13: Please provide p values in addition to 95% CIs for absolute changes in obesity prevalence.

25. Results: Page 12: Please remove the terms “dramatically” and “substantially” from the following sentences. If statistical significance is meant, please replace with “significantly” where appropriate. “From relative stability in the 1960s to 1980s, the weight for both the genetically predisposed and nonpredisposed increased dramatically from the mid-1980s to the 2000s and then stabilized to a higher level over the past decade. Height-adjusted BMI differed substantially across polygenic score tenths for all ages and at each decade, and the difference varied proportional to the changes in population weight (S5 Fig, S2 Table).”

26. Discussion: Please present and organize the Discussion as follows: a short, clear summary of the article's findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

27. Discussion: Please revise the first sentence to: In this study, we observed that, in transitioning to an obesogenic environment from the 1960s to the late-2010s, the prevalence of obesity and severe obesity increased dramatically for the genetically predisposed yet remained relatively unchanged for the least genetically predisposed.”

28.Discussion: Page 14: Please remove “the most powerful” from this sentence as it is hyperbole. “Combining this unique dataset with the most powerful polygenic predictor to date is the principal strength of our study.” Please also remove other instances of hyperbole.

29. Discussion: please either remove or clarify this sentence, as the meaning is unclear in the context of your results: “Despite being a very heritable trait, our study illustrates that body weight is modifiable proportionate to the presumed degree of the obesogenic exposure.”

30. Discussion: please either remove or clarify these sentences, as it isn’t clear that your results support this conclusion: “The effect of the obesogenic environment on population weight acts partly through enhancing the effect of our genes. The magnitude seems to relate directly with degree of obesogenic exposure in the macroenvironment.”

31. References: Please use the "Vancouver" style for reference formatting, and see our website for other reference guidelines https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references

In particular, please check the formatting of ref. #5 for missing information, and please provide English translations for 27 and 28.

32. Checklist: Thank you for including the completed STROBE checklist as Supporting Information. Please revise the checklist, please use section and paragraph numbers (e.g. “Methods, paragraph 1”), rather than page numbers to refer to locations in the text.

Please add the following statement, or similar, to the Methods: "This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist)."

33. Figure 2: Please provide p values to accompany the ORs reported. Please note in the legend what is represented by each of the 5 panels.

34. Figures 3 and 4: Please provide X axis labels. Please revise the Y axis label to read “Obesity/Severe Obesity Prevalance” or similar. Please use (and explain in the figure legend) different markers or colors to indicate the points and 95% CIs corresponding to the highest and lowest propensity scores.

35. S2 Figure: Please provide Y axis labels.

36. S3 Figure: Is there a chance some of the lines are out of order? The trend of increasing BMI over time doesn’t fit with this plot of BMI distribution for the entire study sample by time of measurement, in particular the 2000-2001 line seems out of place (if this is due to the fact that this was the year when only adolescents participated, please make note of this in the legend).

37. S5 Figure: Please use different colors or different marks (and explain in the legend) to indicate the top vs. bottom score data. In the legend, please revise 28,6 to 28.6.

38. S6 Figure: Please indicate in the legend the purpose of the different panels, and please include p values along with the 95% CIs. Please clarify if the X axis is “height adjusted BMI”

39. S7, S8, and S9 Figures: Please use different colors or different marks (and explain in the legend) to indicate the top vs. bottom score data. Please provide X axis labels for all plots.

40. Supporting Information Files: The supplemental information files S1 Table and S2 Table. S3 Table, S4 Table are central to the understanding of the paper. Please incorporate these into the main paper.

41. S1 Table: Please define abbreviations for SD and BMI in the legend.

42. S2 Table: Please also provide the p values associated with these differences. Please clarify if “BMI” represents the difference value, or another measure and provide units if applicable.

43. S3 Table: Please provide p values for these differences. Please clarify what is presented in the columns “Men” and “Women”

44. S4 Table: Please provide p values for these differences. Please make it more clear what is presented in the columns “Men” and “Women”

45. S5 Table: Please provide p values for these differences. Please indicate what is presented in column “BMI” and how this differs from the presentation of data in Table S2.

Comments from the reviewers:

Reviewer #1: I am satisfied with the manuscript and the edits the authors have made to address my previous comments. I therefore recommend that their work is accepted for publication.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 3

Caitlin Moyer

13 Oct 2020

Dear Dr. Brandkvist,

Thank you very much for re-submitting your manuscript "Genetic inequalities in obesity and severe obesity during the obesity epidemic: longitudinal findings from the HUNT Study verified by sibling design" (PMEDICINE-D-20-01911R3) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

Our publications team (plosmedicine@plos.org) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU'VE RECEIVED THE PRODUCTION REQUIREMENTS.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by the editors. In your rebuttal letter you should indicate your response to the editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.

We look forward to receiving the revised manuscript by Oct 20 2020 11:59PM.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

1.From the academic editor: Thank you for including tables 1 and 2. These tables are important to include, but it seems they may be better as supporting information tables, rather than in the main manuscript.

2.From the academic editor: Please clarify further the response regarding the YHUNT2 young adults, suggesting that they were not included in some of these analyses. Your response in the first paragraph of the results is unclear: ”Hoping to fully utilize the wide age range of the dataset, we included BMI measurements of adolescents available from the 1960s and 2000-01. In the results however, we chose to focus on BMI measurements from adult participants as observations in the adolescent age range were limited (Table 3).” Please clarify whether (and if so, which of) the results include adolescent data or not

3.Title: Please revise to: "Genetic associations with temporal shifts in obesity and severe obesity during the obesity epidemic in Norway: a longitudinal population-based cohort (The HUNT study)"

4.Competing interests: Please remove the sentence: “All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf.” And please change the final sentence from “All authors have no financial relationships with any organizations that might have an interest in the submitted work in the previous five years” to “The authors declare no other competing interests."

5.Data availability statement: Please revise the data availability statement to read: “"Data from the HUNT Study can be made available to qualified researchers upon request to the HUNT Data Access Committee (hunt@medisin.ntnu.no). The data availability policy for the HUNT study is available here: (http://www.ntnu.edu/hunt/data). Data are only available to research groups with a PI affiliated with a Norwegian research institute. The Norwegian Institute of Public Health will consider applications for data from the Tuberculosis screening program through www.helsedata.no. Linkages require ethical clearance by the Regional Ethical Committees, more information is available at https://rekportalen.no/."

6.Abstract: Background: Please revise to: “Our study investigates how changes in population weight and obesity over time are associated with genetic predisposition in the context of an obesogenic environment over six decades, and examines the robustness of the findings using sibling design.

7.Abstract: Please define abbreviations for BMI and HUNT at first use.

8.Abstract: Conclusions: In the second sentence, please remove the word “clearly”

9.Author summary: Please format this section using bullets for each point.

10.Author summary: What did the researchers do and find?: Please revise to” We assessed the changes in prevalence of obesity according to genetic predisposition over six decades…” as your study does not directly investigate the relationship with an obesogenic environment (though that can be an interpretation)

11.Author summary: What do these findings mean?: Please revise the first and second point to a single point: “The results indicate that over the past 6 decades, the least genetically predisposed people seem relatively protected from obesity and almost completely protected from severe obesity whereas the most predisposed people are at risk for both obesity and severe obesity, suggesting an interplay between genes and an increasingly obesogenic environment could play a role in growing differences in obesity risk between individuals with varying genetic predisposition.”

12.Author summary: What do these findings mean? Please revise the third point to: “The findings from this study highlights the need to identify and to address the specific factors that led to the population wide increase in obesity.”

13.In text citations: Please include a space between the word and the bracket of the reference, like this [1].

14. Introduction: 3rd paragraph: Please remove the word “vastly”

15. Methods: Patient and Public Involvement: Please clarify what is meant by “We will seek involvement from a patient organization in the development of an appropriate method of

Dissemination.”

16.Results: First sentence: There is a comma missing from “202 030 BMI measurements”

17. Results: Page 14- please clarify whether “weight” or “BMI” is intended here, as only BMI is presented in the table: “From relative stability in the 1960s to 1980s, the weight for both the genetically predisposed and nonpredisposed increased dramatically from the mid-1980s to the 2000s…”

18. Discussion: first paragraph: Please revise the following sentences in the first paragraph, because your study does not directly assess how the passing of time equates to an obesogenic environment- please revise to “In this study, we observed that, from the 1960s to the late-2010s, the prevalence of obesity and severe obesity increased dramatically for the genetically predisposed yet remained relatively unchanged for the least genetically predisposed.”

And “This suggests an increasing genetic inequality in obesity and severe obesity over time, consistent with the increasingly obesogenic environment[reference] and the increasing variance in BMI seen over time in many countries[26].”

19.Discussion: Page 22: Please qualify with “to the best of our knowledge” or similar: “...this study includes the largest sample size and range of years of assessments and ages to date…”

20.Discussion: Page 23: Please revise to: “In this study we validate our findings in within-sibship analyses, which suggest that neither assortative mating, dynastic effects, nor fine-scale population stratification issues generate the results we see[14, 15, 34].”

21.Figure 1: Please revise the bottom-most box of the figure. It is misleading as the study did not formally assess a gene x environment interaction analysis.

22.Figure 2: Please provide the ORs with 95% CIs on the right to accompany the p values.

23.References: Please use the "Vancouver" style for reference formatting, and see our website for other reference guidelines, particularly for for the formatting of bioRxiv postings, for example.

https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references

24.Table 1 and Table 2: Please define abbreviations for GPS and GRS in the legends. Please include legends that describe what is illustrated in the tables.

25.Table 3: Please provide additional demographic information on the study participants, such as comorbidities, lifestyle, and economic status measures.

26.Table 6: Please edit the typos in the 95% CI column for men (“toTo”), and please use consistent capitalization of “to” throughout.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 4

Caitlin Moyer

5 Nov 2020

Dear Dr. Brandkvist,

On behalf of my colleagues and the academic editor, Dr. Ronald C. Ma, I am delighted to inform you that your manuscript entitled "Genetic associations with temporal shifts in obesity and severe obesity during the obesity epidemic in Norway: a longitudinal population-based cohort (The HUNT study)" (PMEDICINE-D-20-01911R4) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (within 5 business days) and a PDF proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer's (introduced) errors. Please return the copyedited file within 2 business days in order to ensure timely delivery of the PDF proof.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point. Given the disruptions resulting from the ongoing COVID-19 pandemic, there may be delays in the production process. We apologise in advance for any inconvenience caused and will do our best to minimize impact as far as possible.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to https://www.editorialmanager.com/pmedicine, log in, and click on the "Update My Information" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

plosmedicine.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Protocol. Prospective protocol.

    (DOCX)

    S1 Text. Modifications to the prospective protocol with rationale.

    (DOCX)

    S2 Text. Supporting figures and tables.

    (DOCX)

    S1 Checklist. Strengthening the reporting of observational studies in epidemiology.

    (DOC)

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Final revision.docx

    Data Availability Statement

    Data from the HUNT Study can be made available to qualified researchers upon request to the HUNT Data Access Committee (hunt@medisin.ntnu.no). The data availability policy for the HUNT study is available here: (http://www.ntnu.edu/hunt/data). Data are only available to research groups with a PI affiliated with a Norwegian research institute. The Norwegian Institute of Public Health will consider applications for data from the Tuberculosis screening program through www.helsedata.no. Linkages require ethical clearance by the Regional Ethical Committees, more information is available at https://rekportalen.no/.


    Articles from PLoS Medicine are provided here courtesy of PLOS

    RESOURCES